drugset

drugset / Trial / NCT00918814

Dose Ranging and Dose Frequency of LIPO-102

NCT00918814 ↗

Phase 2 Completed 54 enrolled Neothetics, Inc

RandomizedParallel-groupSingle-blindTreatment

Summary

Dose Ranging and Dose Frequency of LIPO-102

Timeline

Start: 2009-06
Primary completion: 2010-02
Completion: 2010-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LIPO-102	Unknown	—	Subcutaneous

Indications